Introduction {#s1}
============

Atopic dermatitis (AD) is a pruritic and chronically relapsing inflammatory skin disease involving disturbed skin barrier functions, cutaneous inflammatory hypersensitivity and defects in the antimicrobial immune defense with a strong genetic background [@pone.0026987-Fonacier1]. Predominant infiltration of Th2 cells is a hallmark of acute atopic AD skin lesions [@pone.0026987-Fiset1]. Most patients with AD have peripheral blood eosinophilia and increased serum IgE levels, which are reflected in an increased frequency of peripheral blood skin-homing Th2 cells producing IL-4, IL-5 and IL-13 [@pone.0026987-Fonacier1]. C-C motif chemokine 22 (CCL22) and CCL17 are high-affinity ligands for CC-chemokine receptor 4 (CCR4) and induce selective migration of Th2 cells [@pone.0026987-Andrew1]. CCL22 plays a crucial role in controlling the trafficking of Th2 cells into sites of allergic inflammation and is considered to be involved in the pathology of AD [@pone.0026987-GuttmanYassky1]. Keratinocytes from patients with AD highly express thymic stromal lymphopoietin (TSLP), and CCL22 is produced by TSLP-treated dendritic cells [@pone.0026987-Soumelis1]. CCL22 is upregulated in lesional atopic dermatitis skin compared with healthy skin [@pone.0026987-GuttmanYassky2], and keratinocytes in the epidermal layer of AD skin express CCL17 and CCL22 [@pone.0026987-Horikawa1]. Serum levels of CCL22 in AD patients are significantly higher than those found in normal controls [@pone.0026987-Shimada1], and the levels correlate positively with disease severity in AD patients [@pone.0026987-Hashimoto1]. Strong positive correlations between the levels of CCL17, CCL22, and total IgE in serum of patients with AD and SCORing Atopic Dermatitis (SCORAD) have also been reported [@pone.0026987-JahnzRozyk1]. Another study reported that overproduction of IgE induced CCL22 secretion from basophils, which are essential for IgE-mediated chronic allergic dermatitis [@pone.0026987-Watanabe1]. These findings prompted us to conduct an association and functional study to test whether genetic variations of *CCL22* contribute to AD susceptibility.

Several association studies using genetic variants of genes *CCL17* and *CCR4* in the CCR4 pathway have been conducted to discover genetic components in the pathogenesis of atopic dermatitis [@pone.0026987-Sekiya1], [@pone.0026987-Tsunemi1]. A promoter polymorphism of *CCL17*, -431C\>T, increases the promoter activity and the 431T allele influences higher serum levels of CCL17 [@pone.0026987-Sekiya1], but genetic variants in the *CCL17* gene are not associated with susceptibility to AD. A recent study also reported that C1014T polymorphism in the *CCR4* gene was not associated with AD [@pone.0026987-Tsunemi1]. However, those studies were performed with small sample sizes and without replication studies. Genetic study of the *CCL22* gene has not been conducted.

In this study, we focused on the *CCL22* gene, resequenced the gene regions including all exons and introns, and carried out linkage disequilibrium mapping. We performed an association study using two independent populations and functional analyses of the related variants.

Results {#s2}
=======

Polymorphisms of the *CCL22* gene and LD mapping {#s2a}
------------------------------------------------

We identified a total of 39 polymorphisms ([Table 1](#pone-0026987-t001){ref-type="table"}). We next performed linkage disequilibrium (LD) mapping and calculated pairwise LD coefficients D′ and r^2^ among the 34 polymorphisms with MAF\>10% using the Haploview 4.2 program ([Figure 1](#pone-0026987-g001){ref-type="fig"}). Seven tag SNPs were selected for association studies using tagger in Haploview 4.2, and these polymorphisms captured 34 of the 34 alleles with a mean r^2^ of 0.990 (r^2^\>0.82). The HapMap JPT database contains genotype data for six SNPs with MAF\>10% in the region (data not shown). The SNPs examined in this study covered all six SNPs shown in the HapMap JPT database.

![Pairwise linkage disequilibrium between 34 SNPs.\
LD was measured by D′/LOD (upper) and r^2^ (lower) estimated using the Haploview 4.2 program (<http://www.broad.mit.edu/mpg/haploview/>). Boxed variants were genotyped in this study.](pone.0026987.g001){#pone-0026987-g001}
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###### Frequencies of polymorphisms of the *CCL22* gene.

![](pone.0026987.t001){#pone-0026987-t001-1}

        SNP[\*](#nt101){ref-type="table-fn"}        Location        Amino acid   MAF[‡](#nt102){ref-type="table-fn"}   NCBI[†](#nt103){ref-type="table-fn"}  
  ---- -------------------------------------- -------------------- ------------ ------------------------------------- -------------------------------------- ----------------------------------
  1                   -3075G/A                 5′-flanking region       \-                      0.125                                rs223884                
  2                   -2938G/A                 5′-flanking region       \-                      0.208                                rs223885                
  3                   -2903T/A                 5′-flanking region       \-                      0.333                                rs223886                
  4                   -2668G/T                 5′-flanking region       \-                      0.458                               rs34569362               
  5                   -2550G/C                 5′-flanking region       \-                      0.458                               rs76295899               
  6                   -2511G/T                 5′-flanking region       \-                      0.458                               rs4784799                
  7                   -2191G/C                 5′-flanking region       \-                      0.042                               rs76720124               
  8                   -1795G/A                 5′-flanking region       \-                      0.458                               rs34885482               
  9                   -1775G/T                 5′-flanking region       \-                      0.083                               rs72784894               
  10                  -1618C/T                 5′-flanking region       \-                      0.458                               rs77239447               
  11                  -1515G/T                 5′-flanking region       \-                      0.333                                rs223887                
  12                  -1338A/G                 5′-flanking region       \-                      0.208                                rs182668                
  13                  -961G/A                  5′-flanking region       \-                      0.208                                rs223888                
  14                  -740A/G                  5′-flanking region       \-                      0.083                               rs3760071                
  15                  -488T/C                  5′-flanking region       \-                      0.333                                rs223889                 [§](#nt104){ref-type="table-fn"}
  16                -215WT/DelG                5′-flanking region       \-                      0.333                               rs3214179                
  17                    5C/A                         exon 1          Ala2Asp                    0.125                               rs4359426                 [§](#nt104){ref-type="table-fn"}
  18                   88C/A                        intron 1            \-                      0.458                               rs2074543                 [§](#nt104){ref-type="table-fn"}
  19                   493T/C                       intron 1            \-                      0.458                               rs72784897               
  20                   559G/A                       intron 1            \-                      0.333                                rs223816                
  21                   902C/T                       intron 1            \-                      0.333                                rs223817                
  22                  2030G/C                       intron 2            \-                      0.208                                rs223818                 [§](#nt104){ref-type="table-fn"}
  23                  2134T/C                       intron 2            \-                      0.208                                rs223819                
  24                  2198T/C                       intron 2            \-                      0.208                                rs223820                
  25                  2314G/A                       intron 2            \-                      0.292                                rs598366                
  26                  2936A/G                       intron 2            \-                      0.125                                rs170359                
  27                  3062A/G                       intron 2            \-                      0.458                               rs73557194               
  28                  3766T/A                       intron 2            \-                      0.042                                                        
  29                  3970G/A                       intron 2            \-                      0.125                                rs223821                
  30              4064WT/InsAAAAC                   intron 2            \-                      0.125                               rs72030112               
  31                  5222T/C                        3′ UTR             \-                      0.125                                rs170360                
  32                5978WT/DelT                      3′ UTR             \-                      0.125                               rs57450696               
  33                  5979C/G                        3′ UTR             \-                      0.375                               rs57186204               
  34                  6089T/C                        3′ UTR             \-                      0.125                                rs223823                
  35                  6621A/G                        3′ UTR             \-                      0.458                                rs121565                 [§](#nt104){ref-type="table-fn"}
  36                  6910G/A                        3′ UTR             \-                      0.417                                rs658559                 [§](#nt104){ref-type="table-fn"}
  37                  7858C/T                  3′-flanking region       \-                      0.458                               rs3859048                 [§](#nt104){ref-type="table-fn"}
  38                  7883G/A                  3′-flanking region       \-                      0.458                                rs72301                 
  39                  8021G/A                  3′-flanking region       \-                      0.042                               rs11865093               

\*Numbering according to the genomic sequence of *CCL22* (AC003665). Position 1 is the A of the initiation codon.

Minor allele frequencies (MAF) in the screening population (N = 12).

NCBI, number from the dbSNP of NCBI (<http://www.ncbi.nlm.nih.gov/SNP/>).

SNPs were genotyped in this study.

Association of *CCL22* SNPs with susceptibility to atopic dermatitis {#s2b}
--------------------------------------------------------------------

We recruited 916 cases and 1,032 control subjects for the 1^st^ population and 1,034 cases and 1,004 control subjects for the 2nd population, respectively ([Table 2](#pone-0026987-t002){ref-type="table"}). We genotyped seven tag SNPs and all genotype frequencies are shown in [Table 3](#pone-0026987-t003){ref-type="table"}. The rs4359426 (A2D) SNP was associated with AD under an additive genotype model by logistic regression analysis in the first population (*P* = 0.0072; OR, 0.77; 95% CI, 0.64--0.93) ([Table 3](#pone-0026987-t003){ref-type="table"}). In a replication study, rs4359426 was also associated with AD in the second population (*P* = 0.00037; OR, 0.71; 95% CI, 0.59--0.86) ([Table 3](#pone-0026987-t003){ref-type="table"}). The direction of association of the SNP was similar in both of the populations. We combined the results using inverse variance method, and observed a significant association at rs4359426 (meta-analysis, *P* = 0.0000096; OR, 0.74; 95% CI, 0.65--0.85) ([Table 3](#pone-0026987-t003){ref-type="table"}). We next performed further mapping analyses using two genetic variants, rs170360 and rs223823. The two SNPs were selected from among SNPs that were in strong LD (r^2^\>0.87) with rs4359426 ([Figure 2](#pone-0026987-g002){ref-type="fig"}). Among the three variants, the strongest association was observed at rs4359426 ([Table 4](#pone-0026987-t004){ref-type="table"}).

![Pairwise linkage disequilibrium (r^2^) among eight SNPs in strong LD with rs4359426 in 94 control subjects.\
Two tag SNPs, rs170360 and rs223823, were selected for further association study. Underlined SNPs were examined.](pone.0026987.g002){#pone-0026987-g002}

10.1371/journal.pone.0026987.t002

###### Clinical characteristics of the subjects.

![](pone.0026987.t002){#pone-0026987-t002-2}

                                                          Case                                           Control
  ---------------------- ----------------------------------------------------------------------- -----------------------
  **1^st^ population**                                                                           
  Source                  The University of TokyoKeio UniversityKyushu UniversityTakao Hospital    Control volunteers
  Number of samples                                        916                                            1,032
  Ethnicity                                             Japanese                                        Japanese
  Female                                                  43.6%                                           33.0%
  Age (mean ± sd)                                       30.1±9.5                                        48.5±13.7
  **2^nd^ population**                                                                           
  Source                                              BioBank Japan                               University of Tsukuba
  Number of samples                                       1,034                                           1,004
  Ethnicity                                             Japanese                                        Japanese
  Female                                                  43.8%                                           54.4%
  Age (mean ± sd)                                       30.8±12.7                                       50.0±9.2

10.1371/journal.pone.0026987.t003

###### Genotype counts and case-control association test results of seven tag SNPs.

![](pone.0026987.t003){#pone-0026987-t003-3}

                    Allele          Case                       Control                Frequency of allele 2                      
  ---------------- -------- ------ ------ ----- ------ ------ --------- ----- ------ ----------------------- ------- ----------- ------------------
  1st population                                                                                                                 
  rs223889           T/C     321    435    151   907    360      502     161   1023           0.406           0.403     0.82             \-
  rs4359426          C/A     706    191    12    909    736      269     16    1021           0.118           0.147    0.0072     0.77(0.64--0.93)
  rs2074543          G/C     386    404    113   903    447      469     110   1026           0.349           0.336     0.39             \-
  rs223818           A/G     563    311    39    913    596      369     56    1021           0.213           0.236     0.093            \-
  rs121565           A/G     294    439    173   906    325      509     195   1029           0.433           0.437     0.82             \-
  rs658559           G/A     333    434    134   901    374      491     162   1027           0.390           0.397     0.65             \-
  rs3859048          C/T     399    410    103   912    466      448     108   1022           0.338           0.325     0.40             \-
  2nd population                                                                                                                 
  rs223889           T/C     369    497    163   1029   364      485     150   999            0.400           0.393     0.65             \-
  rs4359426          C/A     815    202    12    1029   722      249     22    993            0.110           0.148    0.00037    0.71(0.59--0.86)
  rs2074543          G/C     404    484    133   1021   418      459     120   997            0.367           0.351     0.26             \-
  rs223818           A/G     647    331    42    1020   585      351     57    993            0.203           0.234     0.019     0.84(0.72--0.97)
  rs121565           A/G     317    530    179   1026   317      500     180   997            0.433           0.431     0.92             \-
  rs658559           G/A     389    486    154   1029   363      479     148   990            0.386           0.391     0.71             \-
  rs3859048          C/T     425    484    117   1026   441      446     113   1000           0.350           0.336     0.35             \-
  Combined                                                                                                                       
  rs223889           T/C     690    932    314   1936   724      987     311   2022           0.403           0.398     0.63             \-
  rs4359426          C/A     1521   393    24    1938   1458     518     38    2014           0.114           0.147   0.0000096   0.74(0.65--0.85)
  rs2074543          G/C     790    888    246   1924   865      928     230   2023           0.359           0.343     0.16             \-
  rs223818           A/G     1210   642    81    1933   1181     720     113   2014           0.208           0.235    0.0044     0.86(0.77--0.95)
  rs121565           A/G     611    969    352   1932   642     1009     375   2026           0.433           0.434     0.93             \-
  rs658559           G/A     722    920    288   1930   737      970     310   2017           0.388           0.394     0.56             \-
  rs3859048          C/T     824    894    220   1938   907      894     221   2022           0.344           0.330     0.21             \-

*P* values of the two populations were calculated by logistic regression analysis under an additive model. The combined *P* values were calculated using the inverse variance method. OR, odds ratio; CI, confidence interval; -, not significant.

10.1371/journal.pone.0026987.t004

###### Genotype counts and case-control association test results for SNPs rs4359426, rs170360 and rs223823.

![](pone.0026987.t004){#pone-0026987-t004-4}

                    Allele          Case                      Control               Frequency of allele 2                      
  ---------------- -------- ------ ------ ---- ------ ------ --------- ---- ------ ----------------------- ------- ----------- ------------------
  1st population                                                                                                               
  rs4359426          C/A     706    191    12   909    736      269     16   1021           0.118           0.147    0.0072     0.77(0.64--0.93)
  rs170360           T/C     695    199    12   906    734      269     20   1023           0.123           0.151     0.011     0.78(0.65--0.95)
  rs223823           T/C     728    170    11   909    765      252     10   1027           0.106           0.132    0.0093     0.77(0.63--0.94)
  2nd population                                                                                                               
  rs4359426          C/A     815    202    12   1029   722      249     22   993            0.110           0.148    0.00037    0.71(0.59--0.86)
  rs170360           T/C     792    220    19   1031   728      238     26   992            0.125           0.146     0.055     0.84(0.70--1.00)
  rs223823           T/C     823    189    8    1020   780      193     19   992            0.100           0.116     0.11      0.85(0.70--1.04)
  Combined                                                                                                                     
  rs4359426          C/A     1521   393    24   1938   1458     518     38   2014           0.118           0.147   0.0000096   0.74(0.65--0.85)
  rs170360           T/C     1487   419    31   1937   1462     507     46   2015           0.123           0.151    0.0017     0.81(0.72--0.93)
  rs223823           T/C     1551   359    19   1929   1545     445     29   2019           0.106           0.132    0.0030     0.81(0.70--0.93)

*P* values of the two populations were calculated by logistic regression analysis under an additive model.

The combined *P* values were calculated using the inverse variance method. OR, odds ratio; CI, confidence interval.

Contribution of 5′UTR rs4359426 SNP to mRNA expression levels of *CCL22* {#s2c}
------------------------------------------------------------------------

Next, using allele-specific transcript quantification (ASTQ), we evaluated whether the related variants could affect the mRNA expression level in EBV-transformed lymphoblastoid cells. As rs4359426 was located at the 16th nucleotide from the 5′ end of the *CCL22* gene (NM_002990.3), we were not able to design primers of the SNP for ASTQ analysis. We therefore designed PCR primers to encompass a SNP in the 3′-UTR of *CCL22* (rs170360) that was in strong LD with rs4359426 ([Figure 3A](#pone-0026987-g003){ref-type="fig"}). We isolated total RNA from 24 cell lines that were heterozygous with rs170360, and genomic DNA was used as a control for equal biallelic representation. Predicted haplotype frequencies are shown in [Figure 3B](#pone-0026987-g003){ref-type="fig"}. The ratio of PCR products was approximately 1.6 for cDNAs and 1.0 for genomic DNA from 21 subjects who were heterozygous for rs4359426 ([Figure 3C](#pone-0026987-g003){ref-type="fig"}, left panel); however, such differences were not observed in cells from three subjects who were homozygous for the C allele at rs4359426 ([Figure 3C](#pone-0026987-g003){ref-type="fig"}, right panel). These results implied an effect of rs4359426 and/or variants in strong LD with rs4359426 on mRNA expression levels of *CCL22*. rs4359426 and rs170360 are in absolute LD in the HapMap Caucasian populations. We further examined the expression patterns of rs4359426 and rs170360 using Genevar 3.0.2 dataset, and confirmed that the expression patterns were similar to our findings (data not shown).

![Allelic imbalance of gene expression of *CCL22* in EBV-transformed cells with heterozygous genotypes.\
(**A**) Genomic structures, locations and LD of the two SNPs. (**B**) Haplotypes for the two SNPs in the 1^st^ population. (**C**) The allelic ratio of PCR products from individuals. Heterozygous (left) and homozygous (right) at rs4359426. \*Two-tailed *P* = 0.0000006 by the Mann-Whitney U test.](pone.0026987.g003){#pone-0026987-g003}

Transcription factor binding to the rs223821 SNP {#s2d}
------------------------------------------------

As rs4359426 was in absolute LD with rs170359, rs223821 and rs72030112 (n = 94) ([Figure 2](#pone-0026987-g002){ref-type="fig"}), we further examined the allelic differences of these three SNPs in the binding of nuclear proteins by electrophoretic mobility shift assay (EMSA). We could not find any specific binding of nuclear factor(s) to oligonucleotides containing rs170359 and rs72030112. However, we observed that the signal intensity of the DNA-protein complex derived from the G allele of rs223821 was higher than that from the A allele in the presence of THP-1 nuclear extract stimulated with LPS (1 µg/ml) ([Figure 4](#pone-0026987-g004){ref-type="fig"}). We confirmed that the complex was diminished by an excess amount of a non-labeled allele-specific competitor probe ([Figure 4](#pone-0026987-g004){ref-type="fig"}). This result suggested that an unidentified nuclear factor(s) interacted with the genomic region at intron 2 of *CCL22* and the SNP might have an allele-specific effect on expression through varying affinity for a transcription factor.

![Electrophoretic mobility shift assays of rs223821.\
EMSA was performed using nuclear extracts from THP-1 cells stimulated with LPS (1.0 µg/ml) for 1 hour. DIG-labeled oligonucleotides corresponding to the G allele (lanes 1--5) and A allele (lanes 6--10) were used as probes. Three independent experiments were performed with similar results.](pone.0026987.g004){#pone-0026987-g004}

Discussion {#s3}
==========

CCL22 plays an important role in the recruitment of Th2 cells into the inflammatory lesions of Th2-related diseases such as AD [@pone.0026987-Yamashita1]. A recent study reported upregulation of *CCL17*, *CCL18* and *CCL22* expression in patients with AD, and suggested that the disease-specific chemokines might recruit specific memory T-cell subsets into the skin [@pone.0026987-Fujita1]. The plasma levels of CCL22 are significantly elevated in AD patients, and the values strongly correlate with disease severity [@pone.0026987-Horikawa1], [@pone.0026987-JahnzRozyk1]. We identified and replicated the rs4359426 (A2D) variant of *CCL22*, which was significantly associated with AD. rs4359426 is a non-synonymous SNP and causes an amino acid substitution in the signal peptide-encoding region. We examined the influence of the amino acid substitution on the structure using SIFT (Sorting Intolerant From Tolerant) software, and the substitution at position 2 from Ala to Asp was predicted to be tolerated. In addition, no possible impacts of the amino acid substitution on the structure and function of CCL22 were predicted by PolyPhen-2 (polymorphism phenotyping v2).

Functional analyses of the related variants of *CCL22* polymorphisms showed that the susceptible allele of rs4359426 might be involved in higher mRNA expression in ASTQ analysis. We confirmed that the expression patterns from Genevar 3.0.2 dataset were similar to our findings. We also demonstrated that the genomic fragment including the risk allele of rs223821 had much higher binding affinity to the nuclear factor(s). Although it is unclear whether higher mRNA expression is influenced by altering expression enhancer activity or mRNA stability, polymorphisms in the *CCL22* gene appear to be a genetic component of the pathologic mechanisms leading to atopic dermatitis, putatively via increased *CCL22* mRNA expression.

Genetic studies reveal underlying cellular pathways, and in some cases, point to new therapeutic approaches. A recent study using a humanized model of asthma showed a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation [@pone.0026987-Perros1]. In the study, administration of a CCR4-blocking antibody abolished airway eosinophilia, goblet cell hyperplasia, IgE synthesis and bronchial hyperreactivity [@pone.0026987-Perros1]. IL-13 is an important mediator of Th2 immune responses, and there many IL-13-positive cells in AD skin lesions [@pone.0026987-Hamid1]. A recent study has shown that IL-13 induces a significant increase in the expression of CCL22 in human keratinocytes, and blocking of CCL22 in IL-13-stimulated cells results in 70--90% inhibition in migration of CD4+CCR4+ T cells [@pone.0026987-Purwar1]. These findings suggest that targeting the CCL22/CCR4 pathway might be therapeutically efficacious as a new treatment for atopic dermatitis.

The involvement of CCL22 has been reported in several immune-mediated diseases. A recent study has shown by immunohistochemistry that CCL22 is not expressed in normal skin and is markedly expressed in the lesions of atopic dermatitis, allergic contact dermatitis, and psoriasis vulgaris [@pone.0026987-Vulcano1]. Another report has shown that CCL22 is present within the synovial membrane in rheumatoid arthritis and osteoarthritis patients and in high amounts in the synovial fluid of patients with rheumatoid arthritis and psoriatic arthritis [@pone.0026987-Flytlie1]. To examine whether the functional SNPs found in this study are associated with those diseases will be needed for understanding of the interconnectivity of the molecular mechanisms underlying distinct diseases.

In summary, we found a significant association between susceptibility to AD and polymorphisms affecting *CCL22* expression in Japanese populations. Our findings strongly support the important role of CCL22 in AD. Although the effect of the non-synonymous SNP on protein function remains unclear, it is likely that related variants play a role in susceptibility to AD in a gain-of-function manner. Further functional analyses and replication studies in other populations are needed; however, our findings provide insights into the pathophysiology of AD.

Materials and Methods {#s4}
=====================

Subjects {#s4a}
--------

A total of 1,950 case subjects with AD were recruited from several hospitals as described [@pone.0026987-Shimizu1]. Case subjects in a second population were obtained from the BioBank Japan [@pone.0026987-Nakamura1]. All case subjects were diagnosed according to the criteria of Hanifin and Rajka [@pone.0026987-Hanifin1]. A total of 1,032 control volunteers in the first set who had no history of AD were recruited by detailed physicians\' interviews. For the second set, a total of 1,004 controls who had never been diagnosed with AD were recruited during their annual health checkup in the University of Tsukuba ([Table 2](#pone-0026987-t002){ref-type="table"}). All individuals were Japanese and gave written informed consent to participate in the study. This research project was approved by the ethics committees at the Institute of Medical Science, the University of Tokyo and the RIKEN Yokohama Institute.

Resequencing of the *CCL22* gene and genotyping {#s4b}
-----------------------------------------------

We first resequenced the *CCL22* region to identify genetic variations using DNA from 12 subjects with AD. We surveyed the gene from 3 kb of the 5′ flanking region to a 1 kb continuous 3′ flanking region of the last exon on the basis of genomic sequences from the NCBI database (NC_000016.9). The PCR product was reacted with BigDye Terminator v3.1 (Applied Biosystems), and sequences were assembled and polymorphisms identified using the SEQUENCHER program (Gene Codes Corporation, Ann Arbor, MI).

Genotyping of the seven SNPs in *CCL22* was performed by the TaqMan™ allele-specific amplification (TaqMan-ASA) method (Applied Biosystems) and multiplex-PCR based Invader assay (Third Wave Technologies).

Allele-specific transcript quantification (ASTQ) {#s4c}
------------------------------------------------

We conducted allelic expression analyses by TaqMan assay using SNP genotyping probes as described [@pone.0026987-Onouchi1]. EBV-transformed lymphoblastoid cells were obtained from the Health Science Research Resources Bank of Japan. Genomic DNA was used as a control for equal biallelic representation. The allelic ratio for each cDNA and genomic DNA was measured.

Electrophoresis Mobility Shift Assay {#s4d}
------------------------------------

EMSA was performed using nuclear extracts from THP-1 cells stimulated with LPS (1.0 µg/ml) for 1 hour. DIG-labeled oligonucleotides corresponding to the G allele (lanes 1--5) and A allele (lanes 6--10) were used as probes. The oligonucleotide sequences were 5′-ATCGCCTGAACCC[G]{.ul}GGAGTTGGAGGTT for the G allele and 5′-ATCGCCTGAACCC[A]{.ul}GGAGTTGGAGGTT for the A allele. For competition, a 100-fold excess of unlabeled G or A allele oligonucleotides or unrelated oligonucleotides (Un) (TFIID) was used.

Statistical analysis {#s4e}
--------------------

We calculated allele frequencies and tested agreement with Hardy-Weinberg equilibrium using a chi-square goodness-of-fit test. We then compared differences in the allele frequencies between case and control subjects by logistic regression analysis under an additive model and calculated odds ratios (ORs) with 95% confidence intervals (CIs). Results for the 1st and 2nd populations were combined by fixed effect inverse-variance method using Genome-Wide Association Meta Analysis (GWAMA, <http://www.well.ox.ac.uk/gwama/tutorial.shtml>) [@pone.0026987-Mgi1]. We applied Bonferroni corrections, the multiplication of *P* values by the number of variants investigated. Corrected *P* values of less than 0.05 were judged to be significant. The expression patterns of SNPs were obtained from Genevar (GENe Expression VARiation) 3.0.2 (Wellcome Trust Sanger Institute). We examined the influence of amino acid substitution on the structure using SIFT software (<http://sift.jcvi.org/>) and PolyPhen-2 (polymorphism phenotyping v2) (<http://genetics.bwh.harvard.edu/pph2/>).

We thank all the patients for participating in the study as well as the collaborating physicians for collecting samples. We also thank the members of BioBank Japan and the Rotary Club of Osaka-Midosuji District 2660 Rotary International in Japan for supporting our study and M. T. Shimizu, H. Sekiguchi, A. I. Jodo, N. Kawaraichi and the technical staff of the Center for Genomic Medicine for providing technical assistance. We thank K. Barrymore for proof reading this document.

**Competing Interests:**The authors have declared that no competing interests exist.

**Funding:**This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology and from the Ministry of Health, Labour and Welfare, Japan. This work was conducted as part of the BioBank Japan Project. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

[^1]: Conceived and designed the experiments: TH MT. Performed the experiments: TH KT STanaka HM TSasaki STakeuchi. Analyzed the data: TH. Contributed reagents/materials/analysis tools: HS KE MS TY SF AM SD TE NH TSakamoto HM TSasaki TE MA HE STakeuchi MF EN YN MK. Wrote the paper: MT. Supervised the study: NK YN.
